SPEER-4E inhibitors refer to a specialized class of chemical agents designed to selectively interact with the SPEER-4E molecular structure. SPEER-4E, an acronym that would typically detail the specific molecular target, suggests a particular protein or enzyme recognized by these inhibitors. The precise mechanism of action for these inhibitors would involve the binding to the active or allosteric sites of the SPEER-4E protein, thereby modulating its function. This interaction is characterized by a high degree of specificity, ensuring that the inhibitor has a strong affinity for the SPEER-4E protein, which is often crucial to achieve the desired level of molecular interaction without affecting other biological pathways. The inhibitors' design is based on the unique three-dimensional configuration of the SPEER-4E protein, taking into account the distribution of charge, hydrophobic and hydrophilic regions, and the dynamic conformational states of the protein to ensure effective binding.
The development of SPEER-4E inhibitors is a complex process that involves a deep understanding of the structure-activity relationships (SAR) governing the interaction between the inhibitor and the SPEER-4E protein. This includes the identification of key functional groups within the inhibitor molecule that are responsible for binding, the optimization of these functional groups to enhance affinity and selectivity, and the assessment of the inhibitor's stability and reactivity within a biological environment. Advanced techniques such as computer-aided drug design (CADD), X-ray crystallography, and nuclear magnetic resonance (NMR) spectroscopy are often employed to elucidate the details of the interaction at an atomic level. The chemical synthesis of SPEER-4E inhibitors may involve multiple steps to construct the inhibitor molecule with high purity and yield. Moreover, the physicochemical properties of the inhibitors, such as solubility, permeability, and metabolic stability, are fine-tuned to ensure that they can maintain their integrity in the complex milieu of a biological system.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that reduces the activity of the mTORC1 complex, which could downregulate the translation of SPEER-4E by inhibiting downstream signaling pathways involved in protein synthesis. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor that impedes the PI3K/Akt/mTOR pathway, potentially decreasing the synthesis and activity of SPEER-4E by inhibiting downstream signals required for its expression. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Another PI3K inhibitor, which could lead to reduced activity of SPEER-4E by blocking PI3K/Akt/mTOR signaling, thereby potentially lowering the expression and function of SPEER-4E. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A MEK inhibitor that obstructs the MEK/ERK pathway, potentially leading to decreased phosphorylation events that could otherwise enhance the stability or activity of SPEER-4E. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor that could reduce the functional activity of SPEER-4E by inhibiting the p38 MAPK pathway, which may be involved in the stress response regulation of SPEER-4E. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, which could lead to a decrease in SPEER-4E activity if SPEER-4E is regulated by stress-activated pathways that involve JNK signaling. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
A Src kinase inhibitor that could impede upstream signals that enhance the activity or stability of SPEER-4E, thereby leading to its decreased functional activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A proteasome inhibitor that could lead to decreased activity of SPEER-4E by enhancing the degradation of improperly folded SPEER-4E proteins or its regulatory proteins. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
Another MEK inhibitor that could decrease the activation of ERK1/2 and subsequently reduce the functional activity of SPEER-4E if it is regulated through this pathway. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
An inhibitor of eukaryotic protein synthesis that could decrease the overall levels of SPEER-4E by blocking its translation on ribosomes. | ||||||